IL23A and myeloid sarcoma: Given the similarity of the results presented here with those from the murine experiments, we conclude that SP, in part through its interaction with proinflammatory cytokines of the IL-12/IL-23, contributes to the development and perpetuation of autoimmune inflammation in the CNS, and it is a strong candidate as a therapeutic target in MS.